77 results about "Depression prevention" patented technology

Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar are as defined and described herein.

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

The invention discloses a Chinese medicine composition preparation for liver soothing and depression relief and a quality control method. The composition is prepared with such raw materials as bupleurum roots, Chinese dates, grassleaved sweetflag rhizome, pinellia tuber, bighead atractylodes rhizome, light wheat, polygala roots, licorice, gardenia, lily and the like. The composition preparation has good effect on depression prevention. The content determination method of the invention has good testing specificity, high stability, good reproducibility and high precision, is more suitable for industrial production and really guarantees the safety, effectiveness and reliability of clinical application.

A disease treatment is provided by controlling the expression of a protein induced by a heat shock factor.The novel compound benzo-1,3-dioxole provides an inhibitor of HSF activity or an inhibitor of inducing the production of a protein regulated by HSF, which inhibits the activity of a heat shock factor, a transcriptional regulatory factor, thereby in turn inhibiting transcription of a structural gene having a heat shock element sequenc in the gene region for transcriptional regulation into RNA, and thus inhibiting translation of the gene into a protein, and resulting in inhibition of inducing production of RNA or protein encoded by the gene. It also provides a drug for treating or preventing cancer through thermotherapy and a drug for treating or preventing stress diseases such as depression.

The invention relates to an application of paeoniflorin in drugs for preventing and treating depression and a pharmaceutical composition thereof, and the pharmaceutical composition contains effective dose of the paeoniflorin and a pharmaceutical acceptable carrier. The pharmaceutical composition can be prepared into various conventional liquid formulations or solid formulations. The paeoniflorin is proved to have better efficacy for the depression and long duration of the efficacy through a rat forced swimming test, a open field test and a new environment feeding inhibition test. The drugs which take the paeoniflorin as an active ingredient and are used for treating and preventing the depression have good effects, long duration, insignificant toxicity and side effect and low price.

Depression and bi-polar depression are treated with an acetyl-L-carnitine (ALCAR), thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents. ALCAR also helps prevents recurrent episodes of depression and bi-polar depression and both provides beneficial membrane phospholipid and high-energy phosphate changes in a brain of human subjects with major depressive disorders (MDD).

Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, R5, R6, n, and m are as defined and described herein.

This invention relates to the treatment and / or prevention of depression and / or anxiety disorders and / or dementia by the administration of an estrogen receptor beta (ERβ) selective agonist either as a single agent, or in combination with other agents.

The invention provides a target gene and a detection kit used for detecting depressive disorder. The target gene used for detecting the depressive disorder is ATP1A1, and nucleotide sequences of a real-time fluorescence quantification PCR (polymerase chain reaction) primer for detecting the gene are shown as SEQ ID NO.2-3. The invention also provides the detection kit used for quantitative detection on ATP1A1. Effective guidance is provided for clinic detection of the depressive disorder by application of the ATP1A1 in preparation of medicines for diagnosing, treating and preventing the depressive disorder.

A pharmaceutical composition for the treatment and / or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype.EP1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

The present invention provides one kind of glossy ganoderma extract for preventing and treating depression and sleep disorder of different causes. The glossy ganoderma extract contains glossy ganoderma polysaccharides, nucleosides, furans, sterols, alkaloids, amino acids and tritrepenes, as well as inorganic ions, organogermanium, etc. It may be mixed with various kinds of depression resisting, tranquilizing and hypnotic medicine and excipient to prepare medicine and health product for preventing and treating depression and sleep disorder of different causes.

Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; "empty" feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating,or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms thatdo not respond to treatment; and combinations thereof. These depressive symptoms can be associated with a depressive state or depressive disorder or can be found sub-clinically or not associated withthese depressive states / disorders (e.g., not part of a syndrome or psychiatric disorder).

The invention discloses a pharmaceutical composition for treating and preventing depression and a preparation method of the pharmaceutical composition. The composition consists of radix bupleuri extract, Chinese angelica extract and white atractylodes rhizome extract. According to the pharmacological experiment results, the pharmaceutical composition can be used for obviously reducing dead time in a mouse forced swimming test and a mice hanging test, remarkably increasing chronic temperature and the weight and the sweet water eccentricity of an unpredictable depression model, and has an obvious anti-depression effect which can reach or exceed that of the existing clinical common anti-depression drugs.

The invention provides an application of catechin (1) shown as a structural formula (I) or pharmaceutical thereof and a pharmaceutical composition thereof in preparing a melatonin receptor agonist, anapplication thereof in preparing medicines for preventing or treating central nervous system disease related to melatonin receptor, and an application in preparing medicines for preventing or treating depression.

An application of the extract of puncturevine caltrop fruit in preparing the medicine, health-care products, or food for preventing and treating depression is disclosed.

The invention relates to a compound of formula (I):wherein:A represents an optionally substituted benzene ring,B represents an imidazoline ring of formula (Ia) or (Ib):and medicinal products containing the same / are useful in treating or in preventing depression, obesity, panic attacks, anxiety, obsessive-compulsive disorders, cognitive disorders, phobias, impulsive disorders associated with the abuse of drugs and withdrawal therefrom, sexual dysfunctions, and Parkinson's disease.

The invention discloses application of arctigenin to the preparation of an anti-depression product. Arctigenin can be applied to preparation of the anti-depression product, particularly drugs, can effectively treat or prevent depression and has a remarkable anti-depression effect. Moreover, arctigenin, as a traditional Chinese medicine natural plant extract, has higher safety and adaptability to a human body, causes little side effects on the human body, can be used for a long time and has a creative significance on study of depression prevention.

The invention discloses a depression-preventing low-swell-shrinking mirror plate which adopts a stainless steel plate as a substrate, and a coating is arranged on the surface of the stainless steel plate. The coating comprises 30-32 parts by weight of an aluminum oxide, 30-32 parts by weight of a hafnium oxide, 30-32 parts by weight of a silicon oxide, 6-8 parts by weight of a europium oxide, 6-8 parts by weight of a silver oxide, 2-4 parts by weight of a palladium oxide and 2-4 parts by weight of a bismuth oxide. According to the scheme, the stainless steel plate is taken as the substrate, the coating on the outer surface of the stainless steel plate takes aluminum oxide, hafnium oxide and silicon oxide as the core, and multiple oxides having a synergistic effect are introduced, so that the surface strength, the surface smoothness, the hot pressing resistance and the depression-prevention performance of the coating of the mirror plate under high pressure are improved effectively; by means of boron nitride, ruthenium oxide and zinc oxide added to the coating, the expansion extent of the coating for larger temperature difference and pressure difference can be improved effectively, and accordingly, bad influence of the overall swell and shrinking of the mirror plate on the using effect and the service life of the mirror plate can be avoided effectively.

Application of astaxanthin as an antidepression medicine belongs to the field of medicine and is characterized in that astaxanthin or derivatives of astaxanthin is taken as pharmacological active component for preparing the antidepression medicine, wherein the derivatives mean pharmaceutically acceptable salts and esters of astaxanthin or glycosides prepared from astaxanthin and saccharide. The medicine is used to treat or prevent depression, and has the advantages of substantial antidepression effect, fast effectiveness, small side effect and the like, and thus the medicine is an excellent antidepression candidate medicine.

Use of a pharmacodynamic active ingredient of ganoderma lucidum in preparing anti-depressant drugs, and anti-depressant drugs comprising the pharmacodynamic active ingredient of ganoderma lucidum, the pharmacodynamic active ingredient being ganoderic acid A or a derivative of ganoderic acid A, the derivatives being glycoside compounds of ganoderic acid A with pharmaceutically acceptable salts, esters or sugar thereof.

The invention relates to moringa oleifera instant coffee, which is prepared from the following raw materials in percentage by mass: 0.05 to 5 percent of moringa oleifera powder, 10 to 70 percent of instant coffee powder and 1 to 70 percent of vegetable fat powder. The moringa oleifera instant coffee has the advantages that through the matched use of the moringa oleifera powder and the instant coffee powder, the refreshing and antifatigue effects of the coffee are shown; the effects of reducing hypertension, reducing hyperlipidemia, reducing hyperglycemia, treating stroke, enhancing the digestion, eliminating fatigue, treating and preventing tristimania and the like of the moringa oleifera are also shown.

The invention discloses use of lentinan as an antidepressant drug, belongs to the field of medicine, and is characterized in that the lentinan or a lentinan derivative is used as an active component to prepare the antidepressant drug; the lentinan derivative is a glycoside prepared from the lentinan and a pharmaceutically acceptable salt, ester or sugar thereof; the antidepressant drug is used for the treatment or prevention of depression, has the advantages of significant anti-depression effect, quick effect, less side effect and the like, and is therefore an excellent anti-depression drug candidate.

The invention discloses application of inosine in preparation of drugs for treatment and / or prevention of depression. Animal experiments prove that inosine has the significant effect of reversing depression-like behaviors, therefore inosine can be used for prevention and treatment of depression, and provides a new method and means for clinical treatment of depression.

The invention discloses an application of a grifron maitake extraction in preparation of an anti-depression drug and belongs to the field of pharmacy. The application is characterized in that biological pharmacodynamic active components of the grifron maitake extraction are used for preparing the anti-depression drug which can be used for treating or preventing depression diseases. The grifron maitake extraction has a significant anti-depression effect, is strong in effect and is free of toxic and side effects in conventional anti-depression drugs, such as causing epilepsy, ataxia and the like, so that the anti-depression drug prepared with the grifron maitake extraction is an excellent anti-depression candidate drug.

The invention provides the application of hydroxytyrosol and derivatives thereof in preparation of antidepressant products, and belongs to the field of biomedicine. Hydroxytyrosol derivative are at least one selected from that group consist of hydroxytyrosol salts, hydroxytyrosol esters and hydroxytyrosol ether, and can be derived from chemical synthesis, microbial fermentation or animal and plantextraction. The products for preventing and treating depression may be medicines, foods, functional foods, and the like. The antidepressant prepared with hydroxytyrosol and its derivatives as activeingredients has the effects of preventing and treating depression and preventing the recurrence of depression, and can be used for reducing the incidence of depression and improving the quality of life of patients with depression.

This invention relates to the field of traditional Chinese medicine, particularly to the application of traditional Chinese medicine composition. The invention provides the application of a traditional Chinese medicine composition comprising Sichuan lovage rhizome and tall gastrodia tuber in the traditional Chinese medicine preparation for increasing the content of serotonin, norepinephrine and dopamine in the brain. This invention also provides the application of the traditional Chinese medicine composition comprising Sichuan lovage rhizome and tall gastrodia tuber in the manufacture of a medicament for the treatment and / or prophylaxis of depression. The experimental results of the invention show that the provided composition can significantly reduce the immobility time in the mice forcing swimming and the tail suspension experiment, and increase the amount of serotonin (5-HT), norepinephrine (NE), Dopamine (DA), whose effect is similar to the positive control drug paroxetine, suggesting that the compositions provided by the present invention will play an important role in the treatment or prevention of depression.

Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I:or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar are as defined and described herein.

Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula (I): or a pharmaceutically acceptable salt thereof, wherein each of R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, n and m are as defined and described herein.